UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis
Clinical trial NCT01973049 · COMPLETED
Trial details
- NCT number
- NCT01973049
- Sponsor
- Bristol-Myers Squibb
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2013-12-01
- Primary completion
- 2014-08-01
- Enrollment
- 202
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.